RVMD vs. ONC, BNTX, TEVA, SMMT, ITCI, GMAB, MRNA, VTRS, RDY, and ASND
Should you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.
Revolution Medicines vs.
Revolution Medicines (NASDAQ:RVMD) and Beigene (NASDAQ:ONC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, community ranking, risk, earnings, dividends and valuation.
Revolution Medicines has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Beigene has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.
Revolution Medicines has higher earnings, but lower revenue than Beigene. Beigene is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
Revolution Medicines has a net margin of 0.00% compared to Beigene's net margin of -25.94%. Beigene's return on equity of -25.12% beat Revolution Medicines' return on equity.
94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 48.5% of Beigene shares are owned by institutional investors. 8.0% of Revolution Medicines shares are owned by insiders. Comparatively, 7.4% of Beigene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Revolution Medicines received 92 more outperform votes than Beigene when rated by MarketBeat users. Likewise, 76.61% of users gave Revolution Medicines an outperform vote while only 60.00% of users gave Beigene an outperform vote.
In the previous week, Revolution Medicines had 7 more articles in the media than Beigene. MarketBeat recorded 11 mentions for Revolution Medicines and 4 mentions for Beigene. Revolution Medicines' average media sentiment score of 0.65 beat Beigene's score of 0.51 indicating that Revolution Medicines is being referred to more favorably in the media.
Revolution Medicines currently has a consensus price target of $66.31, indicating a potential upside of 73.99%. Beigene has a consensus price target of $310.00, indicating a potential upside of 23.39%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Revolution Medicines is more favorable than Beigene.
Summary
Revolution Medicines beats Beigene on 16 of the 19 factors compared between the two stocks.
Get Revolution Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revolution Medicines Competitors List
Related Companies and Tools
This page (NASDAQ:RVMD) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy RVMD Stock Free RVMD Stock Alerts